BRIEF COMMUNICATION

Evidence for the Colonic Origin of Ovarian Cancer Cell Line SW626

Michael T. Furlong, Colleen D. Hough, Cheryl A. Sherman-Baust, Ellen S. Pizer, Patrice J. Morin

Affiliations of authors: M. T. Furlong, C. D. Hough, C. A. Sherman-Baust, P. J. Morin, Laboratory of Biological Chemistry, Gerontology Research Center, National Institute on Aging, Baltimore, MD; E. S. Pizer, Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore.

Correspondence to: Patrice J. Morin, Ph.D., Laboratory of Biological Chemistry, Gerontology Research Center, National Institute on Aging, 5600 Nathan Shock Dr., Baltimore, MD 21224 (e-mail: morinp{at}grc.nia.nih.gov).

Cancer cell lines are an essential tool of cancer research, but their origin can sometimes be difficult to determine with certainty. In addition to contamination with other cell lines during in vitrocultivation, errors can arise during the initial resection from the patient because the organ of origin can sometimes be difficult to determine. This is particularly problematic for ovarian cancer, where a substantial fraction of the cases represent metastases from distant nongenital sites (1). Once in culture and without detailed patient data, it can be difficult or impossible to trace the origin of a particular cell population. The difficulty arises from the fact that cells tend to lose their tissue-specific markers during tumorigenesis and in vitro establishment.

In the course of our study of ß-catenin signaling in ovarian cancer, we discovered several ovarian cancer lines that have constitutively elevated ß-catenin-mediated transcription (Furlong MT, Morin PJ: unpublished results). Deregulation of this pathway results in inappropriate activation of T-cell factor-responsive genes and, in colon cancer, is due to mutations either in ß-catenin or in the tumor suppressor gene adenomatous polyposis coli (APC) (2,3). Our finding of ovarian cell lines with an activated ß-catenin/T-cell factor pathway is consistent with a recent report (4) that ß-catenin is mutated in a subset of ovarian cancers. SW626, a well-studied ovarian cancer cell line, showed high levels of ß-catenin-mediated transcriptional activation but contained a wild-type ß-catenin gene, as assessed by direct sequencing. Surprisingly, however, when a cell lysate of SW626 was probed by immunoblotting with an anti-APC antibody, full-length APC was not detected (Fig. 1,Go A). Instead, SW626 expressed a truncated product of approximately 110 kd. The APC tumor suppressor gene is mutated in the vast majority of all colon cancers (5) but has never been found to be altered in ovarian cancer. Indeed, APC was previously analyzed in 40 sporadic ovarian carcinomas, and no mutations were found (6).



View larger version (64K):
[in this window]
[in a new window]
 
Fig. 1. Analysis of the adenomatous polyposis coli (APC) gene and protein in SW626 cancer cell line. A) Immunoblot analysis using FE-9 antibody (Oncogene Research Products, Cambridge, MA). Lines analyzed are as follows: colon cancer cell line HCT116 (lane 1), which contains a wild-type Apc protein; colon cancer cell line SW480 (lane 2), which expresses a truncated (approximately 140 kd) protein; and cancer cell line SW626 (lane 3). B) Genomic sequence analysis of the APC gene in cancer cell lines SW626 and A2780. For each line, a portion of exon 15 was amplified by use of primer pair TBA2-173 (AATGCATGTGGAACTTTGTGG)/TBA2-171 (CATTAGATGAAGGTGTGGACG) and directly sequenced with the Thermosequenase kit (Amersham Life Science Inc., Arlington Heights, IL) with the use of internal primer TBA2-17 (GCTCTGCTGCCCATACAC). Arrow indicates the single adenine insertion in the APC gene of SW626. The analogous sequence from cell line A2780 is shown as a control for wild-type APC.

 
To identify the APC mutation present in SW626, part of exon 15 was amplified from genomic DNA by the polymerase chain reaction, and the purified fragment was used as a template for direct sequencing. An insertion of one adenine in a tract of four consecutive adenines was found in the APC gene at nucleotide 2941 (A2941) (Fig. 1Go, B). The A2941 insertion is predicted to produce a frameshift along with the generation of an in-frame termination codon nine amino acids downstream of the adenine tract. This mutation was not found in the human gene mutation database (7) but is reminiscent of a type of mutation frequently found in colon cancer (8). It is interesting that no wild-type sequence was present, strongly suggesting hemizygosity at the APC locus. This finding is consistent with the observation that no full-length Apc protein was detected by immunoblotting (Fig. 1Go, A). As a control, the same region of APC was sequenced from ovarian cancer cell line A2780 and was found to be wild type (Fig. 1Go, B). To rule out possible contamination with a colon cancer cell line in our laboratory or at the American Type Culture Collection (Manassas, VA), an SW626 seed stock was obtained from the American Type Culture Collection, and genomic DNA was prepared directly from the frozen cells without cultivation. APC exon 15 was amplified and sequenced as described above. The A2941 insertion was present, demonstrating that this mutation is not the result of an in vitro culturing contamination.

Because the above results suggested that SW626 may be of colonic origin, we decided to investigate this issue further by using immunologic markers often used to differentiate ovarian from colonic primary tumors. SW626 cells were stained with antibodies against cytokeratin (CK) 20, CK7, estrogen receptor/progesterone receptor, CA125, carcinoembryonic antigen, and Calretinin. It has been reported that CK20 and CK7 are the best markers to differentiate colonic from ovarian carcinoma (9,10). Typically, colonic carcinomas are positive for CK20 and negative for CK7; in contrast, ovarian carcinomas are usually positive for CK7 and negative for CK20. The staining pattern of SW626 was completely consistent with a colonic origin because it was positive for CK20 and negative for CK7 (Table 1)Go. These staining data were confirmed by examining the results of an ongoing serial analysis of gene expression (11) in our laboratory. The CK20 transcript was found at relatively high levels in SW626 (0.1% of the total messenger RNAs), whereas the CK7 messenger RNA was not detected in more than 5000 transcripts. The other markers shown in Table 1Go are not as consistently reliable for differentiating ovarian from colonic carcinomas but are still of interest. Estrogen receptor/progesterone receptor, CA125, and Calretinin, which are sometimes positive in ovarian cancer, were negative in SW626, and carcinoembryonic antigen, a marker that is positive in up to 50% of colon cancer specimens (10), was negative in SW626.


View this table:
[in this window]
[in a new window]
 
Table 1. Summary of immunostaining data on SW626 cancer cell line*

 
Our results suggest that SW626 is a cell line of colonic origin. Because of their ability to mimic ovarian primary tumors, colonic carcinomas that have metastasized to the ovaries can be misclassified as ovarian primary tumors (12,13). We suggest the possibility that SW626 may have been misdiagnosed when it was first resected in 1974. This may explain unusual findings in our laboratory and other laboratories, including one report (14) describing the expression of the gastrointestinal tract protein gastrin in SW626. It is impossible to clearly establish the origin of a cell line after many years in culture. At the very least, the data presented herein demonstrate that SW626 does not represent a "typical" ovarian cancer and would suggest caution when this cell line is used.

REFERENCES

1 Petru E, Pickel H, Heydarfadai M, Lahousen M, Haas J, Schaider H, et al. Nongenital cancers metastatic to the ovary. Gynecol Oncol 1992;44:83-6.[Medline]

2 Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a ß-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-7.[Abstract/Free Full Text]

3 Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of ß-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90.[Abstract/Free Full Text]

4 Palacios J, Gamallo C. Mutations in the ß-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res 1998;58:1344-7.[Abstract]

5 Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.[Medline]

6 Allan GJ, Cottrell S, Trowsdale J, Foulkes WD. Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in APC at 5q21-22. Hum Mutat 1994;3:283-91.[Medline]

7 Cooper DN, Ball EV, Krawczak M. The human gene mutation database. Nucleic Acids Res 1998;26:285-7.[Abstract/Free Full Text]

8 Huang J, Papadopoulos N, McKinley AJ, Farrington SM, Curtis LJ, Wyllie AH, et al. APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A 1996;20:9049-54.

9 Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996;9:426-9.[Medline]

10 Lagendijk JH, Mullink H, Van Diest PJ, Meijer GA, Meijer CJ. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-7.[Medline]

11 Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-7.[Abstract]

12 Daya D, Nazerali L, Frank GL. Metastatic ovarian carcinoma of large intestinal origin simulating primary ovarian carcinoma. A clinicopathologic study of 25 cases. Am J Clin Pathol 1992;97:751-8.[Medline]

13 Ulbright TM, Roth LM, Stehman FB. Secondary ovarian neoplasia. A clinicopathologic study of 35 cases. Cancer 1984;53:1164-74.[Medline]

14 Kim H, Evers BM, Banker NA, Greeley GH Jr, Hellmich MR, Thompson, JC, et al. Novel expression and regulation of gastrin gene in human ovarian cancer cell line, SW626. Dig Dis Sci 1998;43:1465-73.[Medline]

Manuscript received December 28, 1998; revised May 14, 1999; accepted June 8, 1999.


This article has been cited by other articles in HighWire Press-hosted journals:


             
Copyright © 1999 Oxford University Press (unless otherwise stated)
Oxford University Press Privacy Policy and Legal Statement